microRNA27a-3p mediates reduction of the Wnt antagonist sFRP-1 in systemic sclerosis

References

• Henderson J, Bhattacharyya S, Varga J, et al. Targeting TLRs and the inflammasome in systemic sclerosis. Pharmacol Ther. 2018;192:163–169.
   Google Scholar
• Allanore Y, Simms R, Distler O, et al. Systemic sclerosis. Nat Rev Dis Primers. 2015;1(1):15002.
   Google Scholar
• Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685–1699.
   Google Scholar
• O’Reilly S. Epigenetics in fibrosis. Mol Aspects Med. 2017;54:89–102.
   Google Scholar
• Henderson J, Distler J, O’Reilly S. The role of epigenetic modifications in systemic sclerosis: a druggable target. Trends Mol Med. 2019;25(5):395–411.
   Google Scholar
• Henderson J, Brown M , Horsburgh S, et al. Methyl cap binding protein 2: a key epigenetic protein in systemic sclerosis. Rheumatology. 2018;key327–key327.
   Google Scholar
• Dees C, Schlottmann I, Funke R, et al. The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis. Ann Rheum Dis. 2014;73(6):1232–1239.
   Google Scholar
• Beyer C, Schramm A, Akhmetshina A, et al. β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis. Ann Rheum Dis. 2012;71(5):761–767.
   Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297.
   Google Scholar
• Frank-Bertoncelj M, Klein K, Gay S. Interplay between genetic and epigenetic mechanisms in rheumatoid arthritis. Epigenomics. 2017;9(4):493–504.
   Google Scholar
• O’Reilly S. MicroRNAs in fibrosis: opportunities and challenges. Arthritis Res Ther. 2016;18(1):11.
   Google Scholar
• van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747–1755.
   Google Scholar
• O’Reilly S, Ciechomska M, Cant R, et al. Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-β (TGF-β) signaling promoting SMAD3 activation and fibrosis via gremlin protein. J Biol Chem. 2014;289(14):9952–9960.
   Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 2001;25(4):402–408.
   Google Scholar
• Huber LC, Distler JHW, Moritz F, et al. Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis Rheumatism. 2007;56(8):2755–2764.
   Google Scholar
• Lafyatis R. Transforming growth factor β–at the centre of systemic sclerosis. Nat Rev Rheumatol. 2014;10(12):706–719.
   Google Scholar
• Wiese KE, Nusse R, van Amerongen R. Wnt signalling: conquering complexity. Development. 2018;145(12):dev165902.
   Google Scholar
• Beyer C, Reichert H, Akan H, et al. Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis. Ann Rheum Dis. 2013;72(7):1255–1258.
   Google Scholar
• Akhmetshina A, Palumbo K, Dees C, et al. Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis. Nat Commun. 2012;3(1):735.
   Google Scholar
• Kim K-I, Jeong D-S, Yoon T-J, et al. Inhibition of collagen production by ICG-001, a small molecule inhibitor for Wnt/β-catenin signaling, in skin fibroblasts. J Dermatol Sci. 2017;86(1):76–78.
   Google Scholar
• Teratani T, Tomita K, Suzuki T, et al. Aortic carboxypeptidase–like protein, a WNT ligand, exacerbates nonalcoholic steatohepatitis. J Clin Invest. 2018;128(4):1581–1596.
   Google Scholar
• Matsuyama M, Nomori A, Nakakuni K, et al. Secreted frizzled-related protein 1 (Sfrp1) regulates the progression of renal fibrosis in a mouse model of obstructive nephropathy. J Biol Chem. 2014;289(45):31526–31533.
   Google Scholar
• Horsburgh S, Fullard N, Roger M, et al. MicroRNAs in the skin: role in development, homoeostasis and regeneration. Clin Sci. 2017;131(15):1923–1940.
   Google Scholar
• Wei J, Bhattacharyya S, Varga J. Peroxisome proliferator-activated receptor γ: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis. Curr Opin Rheumatol. 2010;22(6):671–676.
   Google Scholar
• Wei J, Ghosh AK, Sargent JL, et al. PPARγ downregulation by TGFß in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. Plos One. 2010;5(11):e13778.
   Google Scholar
• Wu L, Wang Q, Guo F, et al. MicroRNA-27a induces mesangial cell injury by targeting of PPARγ, and its in vivo knockdown prevents progression of diabetic nephropathy. Sci Rep. 2016;6:26072.
   Google Scholar
• Zhou L, Liang X, Zhang L, et al. MiR-27a-3p functions as an oncogene in gastric cancer by targeting BTG2. Oncotarget. 2016;7(32).
   Google Scholar
• Li Z, Ji L, Su S, et al. Leptin up-regulates microRNA-27a/b-3p level in hepatic stellate cells. Exp Cell Res. 2018;366(1):63–70.
   Google Scholar
• Beyer C, Huang J, Beer J, et al. Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages. Ann Rheum Dis. 2015;74(6):1317–1324.
   Google Scholar
• Davoodian P, Ravanshad M, Hosseini SY, et al. Effect of TGF-β/smad signaling pathway blocking on expression profiles of miR-335, miR-150, miR-194, miR-27a, and miR-199a of hepatic stellate cells (HSCs). Gastroenterol Hepatol Bed Bench. 2017;10(2):112–117.
   Google Scholar
• Aden N, Nuttall A, Shiwen X, et al. Epithelial cells promote fibroblast activation via IL-1α in systemic sclerosis. J Invest Dermatol. 2010;130(9):2191–2200.
   Google Scholar